Browse > Article
http://dx.doi.org/10.3345/kjp.2010.53.2.195

Surgical outcome of severe pulmonary arterial hypertension secondary to left-to-right shunt lesions  

Lee, Cha Gon (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Jeong, Su-In (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Huh, June (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Kang, I-Seok (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Lee, Heung Jae (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Yang, Ji-Hyuk (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Jun, Tae Gook (Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine)
Publication Information
Clinical and Experimental Pediatrics / v.53, no.2, 2010 , pp. 195-202 More about this Journal
Abstract
Purpose : Despite recent advances in pulmonary hypertension management and surgery, appropriate guidelines remain to be developed for operability in congenital heart disease with pulmonary artery hypertension (PAH). Our aim was to evaluate clinical outcomes of patients with severe PAH who underwent surgical closure of left-to-right shunt lesions (LRSL) on the basis of pulmonary reactivity. Methods : We retrospectively reviewed 21 patients who underwent surgical closure of LRSL with severe PAH (${\geq}8$ Wood unit) from January 1995 to April 2009. The median age at operation was 26 years. Atrial septal defect, ventricular septal defect (VSD), VSD and patent ductus arteriosus (PDA), and PDA was present in 11, 4, 4, and 2 patients, respectively. Results : Operability was based on vasoreactivity of PAH. Of the 21 patients, 5 showed response to pulmonary vasodilator therapy and 8 showed vasoreactivity after balloon occlusion of defects. The remaining 8 patients were considered operable because of significant left-to-right shunt (Qp/Qs ${\geq}1.5$). Five patients underwent total closure of defects and 16 were left with small residual shunts. The median follow-up duration was 32 months. There was no significant postoperative mortality or morbidity. Systolic pulmonary artery pressure (PAP) decreased in all but 2 patients. All patients except 1 showed improvement of New York Heart Association functional class. Conclusion : Closure of LRSL in patients with severe PAH on the basis of pulmonary vasoreactivity seems reasonable. PAP and clinical symptoms improved in most patients. Further research is needed for the evaluation of long-term results.
Keywords
Pulmonary hypertension; Balloon occlusion; Congenital heart disease; Surgery;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Attie F, Rosas M, Granados N, Zabal C, Buendia A, Calderon J. Surgical treatment for secundum atrial septal defects in patients >40 years old. A randomized clinical trial. J Am Coll Cardiol 2001;38:2035-42   DOI   ScienceOn
2 Driscoll D, Allen HD, Atkins DL, Brenner J, Dunnigan A, Franklin W, et al. Guidelines for evaluation and management of common congenital cardiac problems in infants, children, and adolescents. A statement for healthcare professionals from the Committee on Congenital Cardiac Defects of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 1994;90:2180-8   DOI   PUBMED   ScienceOn
3 Schwerzmann M, Zafar M, McLaughlin PR, Chamberlain DW, Webb G, Granton J. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy. Int J Cardiol 2006;110:104-7   DOI   ScienceOn
4 Holzer R, Cao QL, Hijazi ZM. Closure of a moderately large atrial septal defect with a self-fabricated fenestrated Amplatzer septal occluder in an 85-year-old patient with reduced diastolic elasticity of the left ventricle. Catheter Cardiovasc Interv 2005;64:513-8   DOI   ScienceOn
5 Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 2008;129:163-71   DOI   ScienceOn
6 Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537   DOI   ScienceOn
7 Pershukov VV, Pataraia SA, Batyraliev TA, Niiazova-Karben ZA, Sidorenko BA, Preobrazhenskii DV. Recommendations of the Working Group of European Society of Cardiology on diagnosis and treatment of pulmonary arterial hypertension. Kardiologiia 2005;45:84-91   PUBMED
8 Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655-65   DOI   PUBMED   ScienceOn
9 Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007;115:1039-50   DOI   ScienceOn
10 Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65   PUBMED   ScienceOn
11 Beyer J. Atrial septal defect: acute left heart failure after surgical closure. Ann Thorac Surg 1978;25:36-43   DOI   PUBMED   ScienceOn
12 Gatzoulis MA, Freeman MA, Siu SC, Webb GD, Harris L. Atrial arrhythmia after surgical closure of atrial septal defects in adults. N Engl J Med 1999;340:839-46   DOI   ScienceOn
13 Schannwell CM, Steiner S, Strauer BE. Diagnostics in pulmonary hypertension. J Physiol Pharmacol 2007;58:591-602   PUBMED
14 Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958;18:533-47   PUBMED   ScienceOn
15 Balint OH, Samman A, Haberer K, Tobe L, McLaughlin P, Siu SC, et al. Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure. Heart 2008;94:1189-93   DOI   PUBMED   ScienceOn
16 Heath D, Helmholz HF Jr, Burchell HB, Dushane JW, Edwards JE. Graded pulmonary vascular changes and hemodynamic findings in cases of atrial and ventricular septal defect and patent ductus arteriosus. Circulation 1958;18:1155-66   PUBMED   ScienceOn
17 Therrien J, Dore A, Gersony W, Iserin L, Liberthson R, Meijboom F, et al. CCS Consensus Conference 2001 update: recommendations for the management of adults with congenital heart disease. Part I. Can J Cardiol 2001;17:940-59   PUBMED   ScienceOn
18 Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900   DOI   ScienceOn
19 Thanopoulos BD, Tsaousis GS, Djukic M, Al Hakim F, Eleftherakis NG, Simeunovic SD. Transcatheter closure of high pulmonary artery pressure persistent ductus arteriosus with the Amplatzer muscular ventricular septal defect occluder. Heart 2002;87:260-3   DOI   PUBMED
20 Marie Valente A, Rhodes JF. Current indications and contraindications for transcatheter atrial septal defect and patent foramen ovale device closure. Am Heart J 2007;153:81-4   DOI   ScienceOn
21 McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-7   DOI   ScienceOn
22 Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation 1978;58:1107-22   PUBMED   ScienceOn
23 Allcock RJ, O'Sullivan JJ, Corris PA. Atrial septostomy for pulmonary arterial hypertension. Heart 2003;89:1344-7   DOI   PUBMED
24 Heath D, Helmholz HF Jr, Burchell HB, Dushane JW, Kirklin JW, Edwards JE. Relation between structural change in the small pulmonary arteries and the immediate reversibility of pulmonary hypertension following closure of ventricular and atrial septal defects. Circulation 1958;18:1167-74   PUBMED   ScienceOn
25 Rabasseda X. New research and new guidelines in cardiovascular therapy: a report from the European Society of Cardiology Congress 2007. Timely Top Med Cardiovasc Dis 2007;11:E25   PUBMED
26 Bruch L, Winkelmann A, Sonntag S, Scherf F, Rux S, Grad MO, et al. Fenestrated occluders for treatment of ASD in elderly patients with pulmonary hypertension and/or right heart failure. J Interv Cardiol 2008;21:44-9   DOI   ScienceOn
27 Yan C, Zhao S, Jiang S, Xu Z, Huang L, Zheng H, et al. Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart 2007;93:514-8   DOI   PUBMED   ScienceOn
28 Ghosh S, Chatterjee S, Black E, Firmin RK. Surgical closure of atrial septal defects in adults: effect of age at operation on outcome. Heart 2002;88:485-7   DOI   PUBMED
29 Galie N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243-78   DOI   ScienceOn
30 Webb G, Gatzoulis MA. Atrial septal defects in the adult: recent progress and overview. Circulation 2006;114:1645-53   DOI   ScienceOn